An analysis of reports of depression and suicide in patients treated with isotretinoin


      Background: The Food and Drug Administration (FDA) has received reports of depression and suicide in patients treated with isotretinoin. Objective: Our purpose was to provide the number and describe the cases of depression and suicide reported to the FDA in US patients treated with isotretinoin and to consider the nature of a possible association between isotretinoin and depression. Methods: An analysis was made of reports of depression, suicidal ideation, suicide attempt, and suicide in US isotretinoin users voluntarily submitted to the manufacturer and the FDA from 1982 to May 2000 and entered in the FDA's Adverse Event Reporting System database. Results: From marketing of isotretinoin in 1982 to May 2000, the FDA received reports of 37 US patients treated with isotretinoin who committed suicide; 110 who were hospitalized for depression, suicidal ideation, or suicide attempt; and 284 with nonhospitalized depression, for a total of 431 patients. Factors suggesting a possible association between isotretinoin and depression include a temporal association between use of the drug and depression, positive dechallenges (often with psychiatric treatment), positive rechallenges, and possible biologic plausibility. Compared with all drugs in the FDA's Adverse Event Reporting System database to June 2000, isotretinoin ranked within the top 10 for number of reports of depression and suicide attempt. Conclusion: The FDA has received reports of depression, suicidal ideation, suicide attempt, and suicide in patients treated with isotretinoin. Additional studies are needed to determine whether isotretinoin causes depression and to identify susceptible persons. In the meantime, physicians are advised to inform patients prescribed isotretinoin (and parents, if appropriate) of the possibility of development or worsening of depression. They should advise patients (and parents) to immediately report mood swings and symptoms suggestive of depression such as sadness, crying, loss of appetite, unusual fatigue, withdrawal, and inability to concentrate so that patients can be promptly evaluated for appropriate treatment, including consideration of drug discontinuation and referral for psychiatric care. (J Am Acad Dermatol 2001;45:515-9.)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wysowski DK
        • Pitts M
        • Beitz J.
        Depression and suicide in patients treated with isotretinoin.
        N Engl J Med. 2001; 344: 460
        • Szarfman A.
        Data mining of adverse events for Accutane/Roaccutane. Rockville (MD).
        Food and Drug Administration. 2000;
        • O'Neill RT
        • Szarfman A.
        Discussion: Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System by William DuMouchel.
        The American Statistician. 1999; 53 (invited paper): 190-196
        • Restak RM.
        Pseudotumor cerebri, psychosis, and hypervitaminosis.
        J Nerv Ment Dis. 1972; 155: 72-75
        • Feldman MH
        • Schlezinger NS.
        Benign intracranial hypertension associated with hypervitaminosis.
        A. Arch Neurol. 1970; 22: 1-7
        • Henderson CA
        • Highet AS.
        Depression induced by etretinate.
        Br Med J. 1989; 298: 964
        • Logan RA.
        Efficacy of etretinate for the PUVA-dependent psoriatic.
        Clin Exp Dermatol. 1987; 12: 98-102
        • Borbujo Martinez JM
        • Casado Jimenez M
        • Garijo Lopez MB
        • Soto Melo J.
        • Etretinate
        Depression and behavioral changes: case report.
        Reactions. 28 May 1988; No. 203: 7
        • Zetterstrom RH
        • Simon A
        • Giacobini MMJ
        • Eriksson U
        • Olson L.
        Localization of cellular retinoid-binding proteins suggests specific roles for retinoids in the adult central nervous system.
        Neuroscience. 1994; 62: 899-918
        • Zetterstrom RH
        • Lindqvist E
        • Mata de Urquiza A
        • Tomac A
        • Eriksson U
        • Perlmann T
        • Olson L.
        Eur J Neurosci. 1999; 11: 407-416
        • LeDoze F
        • Debruyne D
        • Albessard F
        • Barre L
        • Defer GL.
        Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat.
        Drug Metab Dispos. 2000; 28: 205-208
        • Krezel W
        • Ghyselinck N
        • Samad TA
        • Dupe V
        • Kastner P
        • Borrelli E
        • et al.
        Impaired locomotion and dopamine signaling in retinoid receptor mutant mice.
        Science. 1998; 279: 863-867
        • Hazen PG
        • Carney JF
        • Walker AE
        • Stewart JJ.
        Depression: a side effect of 13-cis-retinoic acid therapy.
        J Am Acad Dermatol. 1983; 9: 278-279
        • Scheinman PL
        • Peck GL
        • Rubinow DR
        • DiGiovanna JJ
        • Abangan DL
        • Ravin PD.
        Acute depression from isotretinoin.
        J Am Acad Dermatol. 1990; 22 ([letter]): 1112-1114
        • Byrne A
        • Hnatko G.
        Depression associated with isotretinoin therapy.
        Can J Psychiatry. 1995; 40 ([letter]): 567
        • Byrne A
        • Costello M
        • Greene E
        • Zibin T.
        Isotretinoin therapy and depression—evidence for an association.
        Ir J Psych Med. 1998; 15: 58-60
        • Bravard P
        • Krug M
        • Reznick JC.
        Isotretinoin and depression: care is needed.
        Nouv Dermatol. 1993; 12: 215
        • Duke EE
        • Guenther L.
        Psychiatric reactions to retinoids.
        Can J Dermatol. 1993; 5: 467
        • Bruno NP
        • Beacham BE
        • Burnett JW.
        Adverse effects of isotretinoin therapy.
        Cutis. 1984; 33: 484-489
        • Middlecoop T.
        Roaccutane (isotretinoin) and the risk of suicide: case report and a review of the literature and pharmocovigilance reports.
        J Pharm Pract. 1999; 12: 374-378
        • Hoyert DL
        • Kochanek KD
        • Murphy SL
        Deaths: final data for 1997.
        National Vital Stat Rep. 1999; vol 47 (Hyattsville (MD): National Center for Health Statistics)
        • Nelson R.
        Pharmacoepidemiologic analysis of Accutane-associated psychiatric events.
        in: Presentation for Hoffman-La Roche at FDA's Dermatologic and Ophthalmic Drugs Advisory Committee meeting, Gaithersburg, MdSept 19, 2000
        • Gupta MA
        • Gupta AK.
        Depression and suicidal ideation in dermatology patients with acne, alopecia areata, and atopic dermatitis and psoriasis.
        Br J Dermatol. 1998; 139: 846-850
        • Cotterill JA
        • Cunliffe WJ.
        Suicide in dermatological patients.
        Br J Dermatol. 1997; 137: 246-250
        • Niemeier V
        • Kupfer J
        • Demmelbauer-Ebner M
        • Stangier U
        • Effendy I
        • Gieler U.
        Coping with acne vulgaris.
        Dermatology. 1998; 196: 108-115
        • Kellet SC
        • Gawkrodger DJ.
        The psychological and emotional impact of acne and the effect of treatment with isotretinoin.
        Br J Dermatol. 1999; 140: 273-282
        • Chu A
        • Cunliffe WJ.
        The inter-relationship between isotretinoin/acne and depression.
        J Eur Acad Dermatol Venereol. 1999; 12: 263
        • Reinherz HZ
        • Giaconia RM
        • Lefkowitz ES
        • Pakiz B
        • Frost AK.
        Prevalence of psychiatric disorders in a community population of older adolescents.
        J Am Acad Child Adolesc Psychiatry. 1993; 32: 369-377
        • Garrison CZ
        • Waller JL
        • Cuffe SP
        • McKeown RE
        • Addy CL
        • Jackson KL.
        Incidence of major depressive disorder and dysthymia in young adolescents.
        J Am Acad Child Adolesc Psychiatry. 1997; 36: 458-465
        • Jick SS
        • Kremers HM
        • Vasilakis-Scaramozza C.
        Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.
        Arch Dermatol. 2000; 136: 1231-1236
        • Layton AM
        • Knaggs H
        • Taylor J
        • Cunliffe WJ.
        Isotretinoin for acne vulgaris—10 years later: a safe and successful treatment.
        Br J Dermatol. 1993; 129: 292-296
        • Lyons Jones K
        • Adams J
        • Chambers CD
        • Erickson JD
        • Lammer E
        • Polifka J.
        Isotretinoin and pregnancy.
        JAMA. 2001; 285: 2079